14:55 ET -- Moderna is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Shares were up 8% to $84.96 after Moderna and partner Merck disclosed positive trial results for an experimental mRNA-based treatment for skin cancer. On Wednesday, shares of Moderna and other makers of Covid-19 vaccines declined after Pfizer warned about slower demand for its Covid-19 products. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)

(END) Dow Jones Newswires

December 14, 2023 15:11 ET (20:11 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Moderna Charts.